Aberdeen Group plc Raises Stock Holdings in Alphatec Holdings, Inc. $ATEC

Key Points

• Aberdeen Group plc increased its stake in Alphatec Holdings, Inc. by 5.3% in the first quarter, now owning 1,131,707 shares valued at approximately $11.48 million.
• Despite a recent stock decline of 0.4%, Alphatec reported positive earnings, with $0.02 EPS for the last quarter, exceeding analysts' expectations.
• The company's stock has received multiple "buy" ratings from analysts, with an average price target of $18.50, reflecting confidence in its future performance.

Aberdeen Group plc grew its stake in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 5.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,131,707 shares of the medical technology company's stock after purchasing an additional 56,995 shares during the period. Aberdeen Group plc owned approximately 0.77% of Alphatec worth $11,476,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its holdings in Alphatec by 68.3% during the 1st quarter. Russell Investments Group Ltd. now owns 336,463 shares of the medical technology company's stock valued at $3,412,000 after acquiring an additional 136,577 shares during the period. Motley Fool Asset Management LLC bought a new position in Alphatec in the first quarter worth approximately $6,346,000. Motley Fool Wealth Management LLC bought a new position in shares of Alphatec in the 1st quarter worth $9,070,000. Nuveen LLC purchased a new stake in shares of Alphatec during the first quarter valued at about $135,874,000. Finally, King Luther Capital Management Corp lifted its position in Alphatec by 19.1% during the first quarter. King Luther Capital Management Corp now owns 859,370 shares of the medical technology company's stock valued at $8,714,000 after acquiring an additional 137,901 shares during the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on ATEC shares. Piper Sandler reaffirmed an "overweight" rating and issued a $15.00 price objective (up from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Wall Street Zen raised Alphatec from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Barclays reaffirmed an "overweight" rating and issued a $22.00 price objective (up previously from $21.00) on shares of Alphatec in a report on Monday, August 4th. Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 target price on shares of Alphatec in a research note on Friday, May 2nd. Finally, Canaccord Genuity Group restated a "buy" rating and set a $20.00 price target on shares of Alphatec in a research report on Friday, August 1st. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Alphatec has a consensus rating of "Buy" and a consensus price target of $18.50.

Insider Buying and Selling at Alphatec

In other news, COO Scott Lish sold 6,323 shares of the firm's stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $16.01, for a total value of $101,231.23. Following the sale, the chief operating officer directly owned 658,707 shares in the company, valued at approximately $10,545,899.07. This trade represents a 0.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Tyson Eliot Marshall sold 18,092 shares of Alphatec stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $14.91, for a total value of $269,751.72. Following the sale, the general counsel directly owned 438,331 shares of the company's stock, valued at $6,535,515.21. This trade represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 410,247 shares of company stock valued at $5,376,804. Insiders own 22.80% of the company's stock.

Alphatec Stock Down 1.9%

Shares of NASDAQ ATEC traded down $0.30 during midday trading on Monday, hitting $15.84. The company's stock had a trading volume of 1,536,977 shares, compared to its average volume of 3,222,100. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $16.47. The business's fifty day simple moving average is $12.47 and its two-hundred day simple moving average is $11.60. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77. The firm has a market capitalization of $2.34 billion, a price-to-earnings ratio of -14.02 and a beta of 1.05.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.08. The business had revenue of $185.54 million for the quarter, compared to analysts' expectations of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%.The company's revenue for the quarter was up 27.5% compared to the same quarter last year. During the same period last year, the firm earned ($0.29) earnings per share. Alphatec has set its FY 2025 guidance at EPS. On average, equities analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.